Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54 Clinical Trial Not Allowed)
Funding Opportunity RFA-CA-22-055 from the NIH Guide for Grants and Contracts. The overall goal of this FOA is to establish an agile and effective network infrastructure that undertakes collaborative research to discover molecularly or immunologically targeted agents designed to prevent or intercept oncogenic process in high-risk populations for precision cancer prevention and interception. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 13, 2022 Category: Research Source Type: funding
Dear Colleague Letter: Submission of Proposals to NSF Programs that Address the Interdisciplinary Topics of Theoretical Physics Approaches to Aging, Cancer Biology, and Neurodegenerative Disorders
Available Formats: HTML: https://www.nsf.gov/pubs/2022/nsf22119/nsf22119.jsp?WT.mc_id=USNSF_25&WT.mc_ev=clickPDF: https://www.nsf.gov/pubs/2022/nsf22119/nsf22119.pdf?WT.mc_id=USNSF_25&WT.mc_ev=clickDocument Number: nsf22119Public Comment: This is an NSF Program Announcements and Information item. (Source: NSF Program Announcements and Information)
Source: NSF Program Announcements and Information - September 8, 2022 Category: Science Source Type: funding
Request for Information (RFI): Seeking Input for the National Cancer Institute (NCI) on Expanding the Development of the Integrated Canine Data Commons
Notice NOT-CA-22-125 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 6, 2022 Category: Research Source Type: funding
NCI Cancer Moonshot Scholars Diversity Program (CMSDP) (R01 Clinical Trial Optional)
Funding Opportunity RFA-CA-22-050 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the Cancer Moonshot Scholars Diversity Program (CMSDP) and solicits R01 grant applications that propose independent research projects within the scientific mission of the National Cancer Institute (NCI). The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators (ESIs) awardees from underrepresented groups (URGs), while promoting scientific advancements through diversification of NCIs investigator pool. Investigators from diverse backgrounds, including thos...
Source: NIH Funding Opportunities (Notices, PA, RFA) - September 1, 2022 Category: Research Source Type: funding
Pre-Application Webinar for RFA-CA-22-019, Global Implementation Science for Equitable Cancer Control (GlobalISE Cancer Control, U54 Clinical Trial Optional)
Notice NOT-CA-22-124 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 30, 2022 Category: Research Source Type: funding
Notice of Pre-application Webinar for Cancer Adoptive Cellular Therapy Network (Can-ACT) for Adult (RFA-CA-22-028) and Pediatric Cancers (RFA-CA-22-029), and Coordinating Center (RFA-CA-22-030)
Notice NOT-CA-22-123 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 29, 2022 Category: Research Source Type: funding
Cancer Adoptive Cellular Therapy Network (Can-ACT) for Adult Cancers (UG3/UH3 Clinical Trial Required)
Funding Opportunity RFA-CA-22-028 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting UG3/UH3 applications for the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The goal of this collaborative research network will be to stimulate the conduct of early adoptive cellular therapy clinical trials for adult and pediatric solid tumors. The emphasis is on accelerating the advancement of new cell therapy strategies into clinical testing through novel and collaborative approaches to preclinical ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 24, 2022 Category: Research Source Type: funding
Notice of Pre-Application Webinar for RFA-CA-22-031 and RFA-CA-22-032 for Consortium on Translational Research in Early Detection of Liver Cancer
Notice NOT-CA-22-121 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 24, 2022 Category: Research Source Type: funding
Cancer Adoptive Cellular Therapy Network (Can-ACT) Coordinating Center (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-CA-22-030 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting applications for a Coordinating Center for the Cancer Adoptive Cellular Therapy (Can-ACT) network. The Can-ACT network of research sites will advance collaborative and novel approaches for adoptive cell therapy for solid tumors, with an emphasis on the transition from preclinical testing and translational studies to early phase clinical trials. The Coordinating Center will provide leadership to the Can-ACT ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 24, 2022 Category: Research Source Type: funding
Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required)
Funding Opportunity RFA-CA-22-029 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) soliciting UG3/UH3 applications for the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The goal of this collaborative research network will be to stimulate the conduct of early adoptive cellular therapy clinical trials for adult and pediatric solid tumors. The emphasis is on accelerating the advancement of new cell therapy strategies into clinical testing through novel and collaborative approaches to preclinical ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 24, 2022 Category: Research Source Type: funding
Change of Application Due Date for PAR-22-114, Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)
Notice NOT-CA-22-122 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 23, 2022 Category: Research Source Type: funding
The Early Detection Research Network: Clinical Validation Centers (U01 Clinical Trial Optional)
The objectives of the Early Detection Research Network (EDRN; edrn.cancer.gov) are to discover, develop and validate biomarkers and imaging methods to detect early stage cancers and to translate these into clinical tests. The EDRN provides an infrastructure that is essential for this process and has successfully completed more than10 multicenter validation studies. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 19, 2022 Category: Research Source Type: funding
The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed)
Funding Opportunity RFA-CA-22-041 from the NIH Guide for Grants and Contracts. The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers....
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 18, 2022 Category: Research Source Type: funding
Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54 Clinical Trial Not Allowed)
Notice NOT-CA-22-120 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 16, 2022 Category: Research Source Type: funding
Consortium on Translational Research in Early Detection of Liver Cancer: Data Management and Coordinating Center (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-CA-22-032 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a part of an initiative designed to establish a Liver Cancer Consortium to advance translational research focused on early detection of liver cancer. The Consortium will consist of a Data Management and Coordinating Center (DMCC, to be supported by this U24 FOA) and several Translational Research Centers (TRCs, to be supported by the companion U01 FOA, RFA-CA-22-031). The TRCs will conduct studies to improve the surveillance of liver cancer in high-risk populations, increase the fraction of liver...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 15, 2022 Category: Research Source Type: funding
